Extended recombinant polypeptides and compositions comprising same
AssigneeAmunix Pharmaceuticals, Inc.
InventorsVolker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jerrfey L. Cleland
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
Claims1
An isolated extended recombinant polypeptide (XTEN) comprising greater than about 400 to about 3000 amino acid residues, wherein the XTEN is characterized in that:
- (a) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 80% of the total amino acid sequence of the XTEN;
- (b) the XTEN sequence is substantially non-repetitive;
- (c) the XTEN sequence lacks a predicted T-cell epitope when analyzed by TEPITOPE algorithm, wherein the TEPITOPE algorithm prediction for epitopes within the XTEN sequence is based on a score of −9 or greater.
- (d) the XTEN sequence has greater than 90% random coil formation as determined by GOR algorithm;
- and
- (e) the XTEN sequence has less than 2% alpha helices and 2% beta-sheets as determined by Chou-Fasman algorithm.
Dependencies are inferred from the claim text.